Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. [electronic resource]
Producer: 20180223Description: 58142-58147 p. digitalISSN:- 1949-2553
- Acetanilides -- pharmacology
- Adenine -- analogs & derivatives
- Agammaglobulinaemia Tyrosine Kinase
- Animals
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Line, Tumor
- Drug Synergism
- Everolimus -- pharmacology
- Heterocyclic Compounds, 3-Ring -- pharmacology
- Histone Deacetylase Inhibitors -- pharmacology
- Humans
- Hydroxamic Acids -- pharmacology
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Molecular Targeted Therapy -- methods
- Piperidines
- Protein Kinase Inhibitors -- pharmacology
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- Rituximab -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Vorinostat
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.